Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Analyzing Moleculin Biotech (NASDAQ:MBRX) and Incyte (NASDAQ:INCY)
01:28am, Monday, 27'th Apr 2026
Incyte (NASDAQ: INCY - Get Free Report) and Moleculin Biotech (NASDAQ: MBRX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on
Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
08:25am, Thursday, 23'rd Apr 2026
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
08:36am, Tuesday, 21'st Apr 2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidat
Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile
08:36am, Tuesday, 07'th Apr 2026
Access the Moleculin CEO Corner here
Scalable Biotech Manufacturing Unlocks a $14B Market
09:15am, Friday, 27'th Mar 2026
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
08:31am, Monday, 23'rd Mar 2026
HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the 45th subject has been enrolled in its pivotal Phase
HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the year ended December 31, 2025 and pr
Moleculin to Present at 38th Annual ROTH Conference
09:05am, Tuesday, 17'th Mar 2026
– Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
09:00am, Wednesday, 11'th Mar 2026
Access the Moleculin CEO Corner here
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
08:39am, Thursday, 19'th Feb 2026
HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its ex
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
08:20am, Wednesday, 18'th Feb 2026
Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failures First 45 subjects treated on tra
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
08:35am, Tuesday, 17'th Feb 2026
HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of all
Moleculin Biotech Highlights Phase 3 Annamycin AML Catalysts, Eyes Partnering Within 12 Months
01:02am, Monday, 16'th Feb 2026
Moleculin Biotech (NASDAQ: MBRX) CEO and Chairman Walter Klemp outlined the company's near-term priorities and upcoming clinical catalysts during a corporate presentation, emphasizing progress in its
Moleculin Launches CEO Corner Platform to Share Strategic Insights
08:32am, Friday, 13'th Feb 2026
CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company
Moleculin Biotech (NASDAQ:MBRX) Stock Crosses Below Fifty Day Moving Average – Time to Sell?
04:38am, Saturday, 07'th Feb 2026
Moleculin Biotech, Inc. (NASDAQ: MBRX - Get Free Report) shares passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $4.58 and traded as low
